LEGN · NASDAQ
Legend Biotech Corporation
$20.49 +0.12 (+0.59%)
Company overview
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR-B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $3.8B
- Employees
- 2,600
- Headquarters
- Somerset, NJ
- Website
- legendbiotech.com
- CEO
- Ying Huang
- Listed
- June 5, 2020
- P/E
- -15.07
- Dividend yield
- 0.00%
Company financials
- Revenue
- $1.1B
- Gross profit
- $626M
- Operating income
- -$136M
- EBITDA
- -$181M
- Net income
- -$250M
- EPS
- -$1.36
- Total assets
- $1.6B
- Total debt
- $389M
- Gross margin
- 54.99%
- Net margin
- -21.97%
- Earnings yield
- -6.64%
No annual product segmentation.
Showing FY 2025
LEGN
1D
NASDAQ
O19.12H21.04L19.08C20.37+1.10 (+5.71%)Vol674.34K